Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1979-1983

  Mohamed, Mohamed F ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antimicrobial peptides; Lysostaphin; Mice; MRSA; Skin infection

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; FUSIDIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINEZOLID; LYSOSTAPHIN; TRYPTOPHYLLEUCYLARGINYLARGINYLISOLEUCYLLYSYLALANYLTRYPTOPHYLLEUCYLARGINYLARGININE; TRYPTOPHYLLEUCYLARGINYLARGINYLISOLEUCYLLYSYLALANYLTRYPTOPHYLLEUCYLARGINYLARGINYLISOLEUCYLLYSYLALANINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PROTEIN DETERMINATION; SKIN INFECTION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL SKIN INFECTIONS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84908296966     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S72129     Document Type: Article

References (27)

1. Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763–771.
2. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89(3):219–229.
3. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child. 2004;89(1):74–77.
4. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int J Antimicrob Agents. 2004;23(6):577–581.
5. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629–641.
6. Mohamed MF, Hamed MI, Panitch A, Seleem MN. Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrob Agents Chemother. 2014;58(7):4113–4122.
7. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557.
8. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS. Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PloS One. 2013;8(7):e69508.
9. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309–317.
10. Kumar JK. Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol. 2008;80(4):555–561.
11. Desbois AP, Gemmell CG, Coote PJ. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2010;35(6):559–565.
12. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother. 2003;47(5):1589–1597.
13. Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother. 2007;51(2):475–482.
14. Cho JS, Zussman J, Donegan NP, et al. Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections. J Invest Dermatol. 2011;131(4):907–915.
15. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest. 2010;120(5):1762–1773.
16. De Vry CG, Valdez M, Lazarov M, et al. Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol. 2005;125(3):473–481.
17. Ward B, Seal BL, Brophy CM, Panitch A. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J Pept Sci. 2009;15(10):668–674.
18. Lopes LB, Brophy CM, Flynn CR, et al. A novel cell permeant peptide inhibitor of MAPKAP kinase II inhibits intimal hyperplasia in a human saphenous vein organ culture model. J Vasc Surg. 2010;52(6):1596–1607.
19. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol. 2012;78(7):2297–2305.
20. Rubin BK, Tamaoki J. Antibiotics as Anti-inflammatory and Immunomodulatory Agents. Basel: Birkhäuser; 2005.
21. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol. 2011;11(8):505–518.
22. Cho JS, Guo Y, Ramos RI, et al. Neutrophil-derived IL-1β is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PloS Pathog. 2012;8(11):e1003047.
23. Jialal I, Miguelino E, Griffen SC, Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab. 2007;92(8):3136–3140.
24. Wallace HJ, Stacey MC. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers – correlations to healing status. J Invest Dermatol. 1998;110(3):292–296.
25. Cowin AJ, Hatzirodos N, Rigden J, Fitridge R, Belford DA. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen. 2006;14(4):421–426.
26. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476.
27. Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PloS One. 2010;5(3):e9539.